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Objective: We sought to compare minimally invasive coronary artery bypass grafting
(surgical intervention) with percutaneous transluminal coronary angioplasty with pri-
mary stenting (stenting) in patients having an isolated high-grade stenosis (American
College of Cardiology/American Heart Association classification type B2 or C) of the
proximal left anterior descending coronary artery. At 6 months, both procedures were
compared on the basis of quantitative angiography and clinical outcome.
Methods: Both treatments were compared in a single-center, prospective, random-
ized study. The primary end point of this study was quantitative angiographic outcome
at 6 months. The secondary end point was 6-month clinical outcome. Statistical analysis
was performed in accordance with the intention-to-treat principle.
Results: From March 1997 to September 1999, patients with angina pectoris caused
by an isolated high-grade stenosis of the proximal left anterior descending coronary
artery were randomly assigned to surgical intervention (n  51) or stenting (n 
51). At 6 months, quantitative coronary angiography showed an anastomotic ste-
nosis rate of 4% after surgical intervention and a restenosis rate of 29% after
stenting (P  .001). Periprocedural events did not significantly differ between
surgical intervention and stenting. After surgical intervention, 2 patients died; no
patients died after stenting. After 6 months, no significant difference was found for
major adverse cardiac or cerebral events and need for repeat target vessel revascu-
larization. After 6 months, return of angina pectoris, physical work capacity, and use
of antianginal drugs did not significantly differ between treatments.
Conclusions: After 6 months, surgical intervention had a significantly better angio-
graphic outcome than stenting in patients with an isolated high-grade stenosis of the
proximal left anterior descending coronary artery. Clinical outcome did not signif-
icantly differ between treatments.
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Patients with stenosis of the proximal left an-terior descending coronary artery (LAD) of atleast 70% have a significantly longer adjusted3-year survival with conventional coronaryartery bypass grafting (CABG) than with per-cutaneous transluminal coronary angioplasty
(PTCA).1 Reported patency rates after PTCA with stenting
of a severe type B2 or C lesion of the proximal LAD are
almost 74% to 76% at 6 months’ follow-up.2-4 In contrast,
reported patency rates after minimally invasive coronary
artery bypass grafting (MICAB) for this lesion are almost
95% to 97%.5,6 No randomized prospective trials have been
reported that compared these 2 revascularization modalities
for these type B2 or C lesions of the proximal LAD in
specific. Therefore we compared, in a single-center, pro-
spective, randomized clinical trial, MICAB with PTCA with
primary stenting for isolated type B2 or C lesions of the
proximal LAD.
We present the 6-month angiographic and clinical out-
come of this long-term ongoing trial.
Patients and Methods
Study Design
Patients with chronic stable angina pectoris of Canadian Cardio-
vascular Society (CCS) class 2 or greater caused by an isolated
type B2 or C lesion of the proximal LAD were selected.2 Patients
had to be eligible for both MICAB and PTCA with primary
stenting by unanimous forum decision of cardiologists and cardiac
surgeons. Patients with overt congestive heart failure, previous
CABG or PTCA procedures, previous myocardial infarction or
creatine kinase MB (CK-MB) increase of twice the normal range
in the last 2 weeks, congenital heart disease, history of cerebro-
vascular accident, or need for a concomitant operation were ex-
cluded. Before inclusion, the patient provided written informed
consent. Included patients were randomly assigned to surgical
intervention or stenting. All patients were followed up for 6
months up to their preplanned coronary angiography.
This study was approved by the Ethics Committee of the
University Hospital Groningen. Cordis Europe did not participate
in the conduct of this study.
Surgical Technique
MICAB was performed through a small left anterior thoracotomy
without cardiopulmonary bypass, as previously described in de-
tail.7 In short, the left internal thoracic artery (LITA) was harvested
under direct vision. The LITA-LAD anastomosis was made during
heparinization (activated clotting time of longer than 300 seconds)
on the beating heart by using a running 8-0 Prolene suture (Ethi-
con, Inc, Somerville, NJ) with a mechanical coronary stabilizer
(Cardio Thoracic Systems, Inc, Cupertino, Calif) and temporary
occlusion of the LAD with a proximal snare. No protamine was
given at the end of the procedure. All patients received 100 mg of
aspirin daily starting on postoperative day 1.
PTCA With Stenting Technique
A coronary guiding catheter of 6F to 8F was used to access the
coronary arteries through the femoral, brachial, or radial approach.
Predilatation of the target lesion was performed with a matched-
size or undersized monorail-type or over-the-wire balloon angio-
plasty catheter. The most optimal stent was implanted at the target
site, covering the entire lesion, as well as any proximal or distal
intimal dissection. A narrowing of 0% by visual estimation or 20%
by quantitative coronary angiography (QCA) was the goal.2 All
patients were pretreated with 500 to 1000 mg of aspirin 24 hours
before PTCA with stenting. A bolus of 10,000 to 15,000 IU of
heparin was administered intravenously after sheath insertion (ac-
tivated clotting time of longer than 300 seconds). No protamine
was given at the end of the procedure. All patients received 100 mg
of aspirin daily and 250 mg of ticlopidin daily from the day of stent
implantation until 1 month after the procedure. We used no
Gp2b3a receptor blockers.
Angiographic Analysis
Six months after the initial procedure, a QCA (CAAS, Pie-Medi-
cal, Maastricht, The Netherlands) was performed. From 2 orthog-
onal views, the percentage stenosis diameter was calculated as a
mean. Successful revascularization in the MICAB group was de-
fined as a percentage stenosis diameter of the anastomosis of less
than 50% of the mid-LITA diameter and in the stent group as a
percentage stenosis diameter in the stented segment of less than
50% of the reference diameter of the LAD.2 The quality of the
revascularization of the target vessel was graded as “no abnormal-
ities or small irregularities,” “nonsignificant stenosis” (20%-50%
luminal stenosis), or “stenotic” (50% luminal stenosis).
End Points and Definitions
The primary end point of the present study was the 6-month
angiographic follow-up. Secondary end points were major adverse
cardiac or cerebrovascular events (MACCEs), angina pectoris
status, use of medication, need for repeat target vessel revascular-
ization, and hospitalization time.
MACCEs were cardiac death, myocardial infarction, and cere-
brovascular accident. Cardiac death was defined as death preceded
by symptoms of cardiac origin and sudden death not preceded by
cardiac symptoms unless clearly of noncardiac origin. Myocardial
infarction was diagnosed on the basis of characteristic electrocar-
diographic findings in combination with elevation of total CK and
CK-MB levels. CK levels more than 2 times the upper limit of
normal laboratory range and a CK/CK-MB ratio of greater than
10% confirmed the diagnosis of myocardial infarction. Cerebro-
vascular accident was defined as stroke, transient ischemic attack,
or reversible ischemic neurologic deficit if confirmed by a neurol-
ogist after computed tomography or magnetic resonance imaging
scanning.
Angina pectoris status at 6 months was specified according to
the CCS classification. Myocardial ischemia was assessed by
means of clinical follow-up and bicycle stress testing at 1 and 6
months after discharge. Myocardial ischemia was defined as typ-
ical or atypical anginal pain at rest or during exercise, which was
confirmed by the appearance of an ST-segment change of larger
than 0.1 mV, T-wave inversion in at least 2 of 12 leads during a
bicycle stress test, or both. Repeat target vessel revascularization
was performed in the presence of symptoms or signs of ischemia
and angiographic restenosis of greater than 50%.
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Statistical Analysis
This study was powered to evaluate the 3-year event-free survival
of the ongoing study. For the evaluation of the angiographic
outcome described in this article, an analysis was planned for 100
patients. For this analysis, no formal sample size calculation was
performed.
Statistical analysis was performed in accordance with the in-
tention-to-treat principle. In this setting patients were evaluated on
the basis of their randomized treatment, irrespective of the treat-
ment actually received. The baseline descriptive statistics for
the continuous variables are given as the mean and SEM. For the
normally distributed continuous variables, differences between
the 2 strategies were evaluated with the Student t test. For skewed
distributed continuous end points (P  .05, Shapiro-Wilk test for
normality), the Mann-Whitney U test was used. For qualitative
parameters (categorical or ordered), frequency counts and percent-
ages of each category were calculated by treatment strategy. The
Fisher exact test or 2 test was used to evaluate the differences
between surgical intervention and stenting.
QCA outcome for both treatments at 6 months’ follow-up was
evaluated with a 2 test. After 6 months’ clinical follow-up, the
effect of surgical intervention and stenting on the number of
sustained MACCEs was evaluated with a survival analysis. Sur-
vival was estimated by using the Kaplan-Meier method. By using
a log-rank test, the distribution of event-free survival between the
2 treatment strategies was compared. A second survival analysis
was performed on MACCEs and repeat target vessel revascular-
ization. All tests were performed to test the (null) hypothesis that
no treatment difference were 2-sided. For all analyses, commer-
cially available computer software (Statistical Analysis System
version 6.12; SAS Institute, Cary, NC) was used.
Results
From March 1997 until September 1999, 102 patients were
included in this study. Baseline characteristics did not sig-
nificantly differ (Table 1). Three patients assigned to MI-
CAB underwent PTCA with stenting: 1 because of severe
chronic obstructive pulmonary disease (COPD) implicating
a high operative risk according to the anesthetist and 2 who
finally refused an operation and preferred PTCA with pri-
mary stenting. According to the statistical intention-to-treat
principle, these patients were analyzed with the surgical
intervention group. Six months’ follow-up was completed
for 100 patients, and after surgical intervention, 2 patients
died.
Surgical Intervention Group
The surgical intervention group consisted of 51 patients, of
whom 3 were primarily treated with PTCA and stenting, as
explained above. MICAB was performed as planned in all
but 1 patient; this operation was converted to a midline
sternotomy because of bleeding. Mean length of stay in the
hospital was 7 days (range, 1-20 days).
One patient had a myocardial infarction 1 day after the
operation because of a stenosis of the anastomosis requiring
PTCA with stenting. One patient died 3 days after the
operation because of an ongoing inferoposterior myocardial
infarction. Autopsy showed a patent graft and anastomosis
of the LITA to the LAD, but the right coronary artery was
infarcted by an unknown cause; autopsy also revealed a
proximal luminal diameter of 40% in the right coronary
artery already known from the preoperative angiography but
not identified as significantly stenotic. One week after dis-
charge, 1 patient died at home for unknown reasons after an
uncomplicated operation and hospitalization period. Return
of angina pectoris of CCS class 2 or greater was found in 3
patients, of whom 2 required repeat target vessel revascu-
larization. One patient was treated with a PTCA of the
anastomosis. One patient was treated for unstable angina
pectoris caused by in-stent restenosis, requiring repeat tar-
get vessel revascularization by means of rotablation and
angioplasty. One patient was treated medically. No patient
had a myocardial infarction from discharge up to 6 months’
follow-up. The adverse events are shown in Table 2.
Stent Group
The stent group consisted of 51 patients. The mean length of
stay in the hospital was 3 days (range, 1-22 days). Five
patients had a myocardial infarction after stenting, 3 as a
result of an occlusion of a diagonal branch, 1 because of an
occlusion of the stent (described below), and 1 because of a
dissection. Return of angina pectoris resulted in (prolonged)
hospitalization in 5 patients. Two patients were treated with
additional medication, and 3 patients required repeat revas-
cularization for in-stent restenosis. One patient was treated
TABLE 1. Patients’ clinical characteristics at baseline
MICAB
(n  51)
PTCA  stent
(n  51)
P
value
Age (y) 60 1.6 61 1.3 .73
Female sex 22% 25% .82
Median weight (kg) 82 85 .27
Hypercholesterolemia 41% 45% .80
Diabetes 8% 18% .23
Hypertension 16% 33% .08
Familial coronary artery disease 46% 50% .84
Past/current smoking 25/37% 28/30% .74
Previous myocardial infarction 24% 18% .63
Duration of angina pectoris
(mo)
16 16 .38
CCS classification .06
Class II 31% 27%
Class III 24% 46%
Class IV 45% 27%
Triple therapy .98
No /ca-ant/l.a.nit. 6% 6%
One of /ca-ant/l.a.nit 33% 31%
At least 2 of /ca-ant/l.a.nit. 61% 63%
Stenosis 75% 1.7% 75% 1.5% .96
, -Blocker; ca-ant, calcium antagonist; l.a.nit., long-acting nitrate.
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twice for in-stent restenosis after the first and fifth days after
PTCA and stenting with a PTCA of the same lesion, even-
tually resulting in an occlusion and anteroseptal myocardial
infarction. One patient was treated with re-PTCA and a
cutting balloon after 2 months, and 1 underwent CABG
after 4.5 months. No patients died. From discharge up to 6
months’ follow-up, no patient had a myocardial infarction
or needed to be hospitalized for another reason. The adverse
events are shown in Table 2.
Angiographic Outcome at 6 Months
Coronary angiography was performed in 96 of 102 patients
because of refusal by 4 patients and the death of 2 patients
(Table 3). QCA showed a stenosis (for definition, see “Pa-
tients and Methods” section) of the anastomosis in 2 pa-
tients after surgical intervention (2/46 [4%]) and restenosis
in 14 patients after PTCA with primary stenting (14/49
[29%]). Therefore, angiographic outcome was significantly
better after surgical intervention than after stenting (P 
.001).
Clinical Outcome at 6 Months
Secondary end points did not differ significantly. Log-rank
testing on MACCEs (P  .33) and on MACCEs plus repeat
target vessel revascularization (P  .21) proved these to be
insignificant outcomes for both procedures (Figures 1 and
2). CCS status, exercise testing with a bicycle stress test,
maximal workload capacity, and peak heart rate did not
differ between the 2 groups (Table 3). Use of antianginal
drugs did not significantly differ, although a slight trend of
less need for antianginal drugs was found after MICAB
(Table 3).
Discussion
We report the first prospective randomized trial comparing
MICAB with PTCA with primary stenting for isolated,
proximal, high-grade (type B2 or C) stenosis of the LAD.
In this study MICAB had a significantly better angio-
graphic outcome than PTCA with stenting at 6 months’
follow-up. MICAB and PTCA with primary stenting did not
significantly differ in regard to periprocedural complica-
tions, MACCEs, CCS status, use of antianginal medication,
exercise test results, or repeat target vessel revascularization
up to 6 months after revascularization. Two patients died in
the MICAB group. An anastomotic problem could be ruled
out in 1 patient at autopsy, and the other patient could not be
evaluated, as explained in the “Results” section. Death did
not occur in the PTCA with stenting group.
Mean hospitalization time after MICAB was 7 days, and
that after PTCA with stenting was 3 days. This shorter
convalescence period reflects the true minimally invasive
character of PTCA with primary stenting.
After 6 months, angiographic outcome (either a nonste-
notic LITA anastomosis in the MICAB group or a nonreste-
notic LAD in the PTCA with stenting group) was signifi-
cantly better in the MICAB group (96% vs 71%, P  .001).
This 6-month patency rate of MICAB (96%) equals earlier
reported off-pump patency rates and the benchmark patency
of on-pump coronary bypass surgery.1,6,8-11 Therefore, the
known long-term ITA graft patency rate of almost 96% after
10 years in on-pump coronary bypass surgery can be ex-
pected for our MICAB population.12 The restenosis rate
after PTCA with stenting (71%) reflects the restenosis prob-
TABLE 2. Adverse events during the first 6 months
MICAB
(n  51)
PTCA  stenting
(n  51)
P
value
Death 2 0 .50
Nonfatal myocardial infarction 1 5 .21
CVA 0 1 1.00
Rethoracotomy 1 0 1.00
Dissection of LAD 0 4 .12
Emergency CABG 0 1 1.00
Atrial fibrillation 2 0 .50
Pericarditis 1 0 1.00
Pleural herniation 1 0 1.00
Wound-healing problem 1 0 1.00
Return of angina pectoris 3 5 .72
Hospitalization for unstable
angina pectoris
1 2 1.00
Restenosis 2 4 .68
Repeat revascularization 2 4 .68
Values are number of patients per clinical event category. The number of
patients with at least one event are presented, and no patient double
counting for multiple events within a category was done. Between cate-
gories, patients are double counted in case of multiple events.
TABLE 3. Patients’ clinical characteristics at 6 months
MICAB
(n  49)
PTCA  stent
(n  51)
P
value
CCS classification .25
Class 0 92% 80%
Class 1 2% 10%
Class 2 6% 8%
Class 3 0% 2%
Class 4 0% 0%
Positive exercise test 12% 20% .41
Peak exercise test (W) 148 6.8 150 5.9 .83
Peak heart rate exercise test
(beats/min)
131 3 126 3 .22
Triple therapy .11
No /ca-ant/l.a.nit. 31% 18%
One of /ca-ant/l.a.nit. 43% 37%
At least 2 of /ca-ant/l.a.nit. 26% 45%
Quality of revascularization .001
No abnormalities or small
irregularities
87% 22%
Nonsignificant stenosis
(20%-50%)
9% 49%
Stenotic (50%) 4% 29%
, -Blocker; ca-ant, calcium antagonist; l.a.nit., long-acting nitrate.
Drenth et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 1 133
A
CD
lem and is a high relative risk for future repeat revascular-
izations and MACCEs.13 Although repeat target vessel re-
vascularization did not differ significantly at 6 months, a
difference can be expected for these 2 reasons after a longer
follow-up period. This was found in a recent prospective
randomized trial comparing conventional CABG with the
ITA with PTCA with primary stenting for proximal, iso-
lated, de novo LAD stenosis (the SIMA trial).14 That study
reported a significant difference in clinical outcome be-
tween the 2 treatment groups in favor of the CABG group
after a mean follow-up period of 2.4 years. This was pri-
marily because of the higher incidence of repeat revascu-
larization in the PTCA with stenting group. In that study the
incidence of death and myocardial infarction was similar in
the 2 treatment groups. Also, the functional class, need for
antianginal drugs, and quality-of-life assessment showed no
significant differences.
In the present study we did not use GP2b3a receptor
blockers after PTCA with stenting. It is suggested that their
use might improve outcome because of a reduced restenosis
Figure 1. Kaplan-Meier curves showing survival free from MACCEs after MICAB (black line) and PTCA with
stenting (dotted line).
Figure 2. Kaplan-Meier curves showing survival free from MACCEs and repeat target vessel revascularization after
MICAB (black line) and PTCA with stenting (dotted line).
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rate.15 In our opinion, however, currently available PTCA
and stenting techniques and adjunctive therapies will not
equal patency rates after CABG (whether conventionally or
minimally invasive). Only when the mechanisms of reste-
nosis are fully understood and restenosis can be prevented
might equal results be obtained.
Our study was initiated to find the optimal, minimally
invasive treatment for complex lesions in the proximal
LAD. On the basis of our results with MICAB and the
promising patency rate for PTCA with stenting, we started
this study on the revascularization options of tomorrow.
Data acquired by means of randomized controlled studies
are lacking on today’s options to revascularize a high-grade
lesion of the proximal LAD. In addition, clinical parameters
(eg, diabetes mellitus comorbidity), stent design, direct
stenting, and the use of GP2b/3a receptor blockers have
major implications for the result of this revascularization
strategy.1,15-17 The clinical implication for PTCA with stent-
ing and MICAB therefore lies in the results of studies like
these and studies with longer follow-up.
Conclusions
After 6 months, surgical intervention has a significantly
better angiographic outcome than stenting in patients with a
high-grade stenosis of the proximal LAD. Clinical outcome
did not significantly differ between treatments.
We acknowledge Trienke Steenhuis, Henny Wijkstra, and Peter
Rasker for data management.
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